ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Clinical Immunology
Volume 121, Issue 1, October 2006, Pages 40-46
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (231 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.clim.2006.05.009    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2006 Published by Elsevier Inc.

Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: A new tool to distinguish disease-specific immunoreactivities

C. Tibertia, Corresponding Author Contact Information, E-mail The Corresponding Author, M. Bonamicob, F. Dottac, A. Verrientia, M. Di Tolaa, E. Liud, M. Ferrib, R. Nennab, A. Picarellia and G.S. Eisenbarthd

aDept. of Clinical Sciences, University of Rome “La Sapienza”, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy bPediatrics, University “La Sapienza”, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy cDepts. of Internal Medicine and of Endocrine and Metabolic Sciences, University of Siena, Italy dBarbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences, Center, CO 80309-0482, USA

Received 3 March 2006; 
accepted 16 May 2006. 
Available online 23 June 2006.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

The aim of the present study was to evaluate the epitope specific humoral human tissue transglutaminase (tTG) immunoreactivity against 3 different human recombinant tTG constructs [(full-length tTG (a.a. 1–687), tTG (a.a. 227–687); tTG (a.a. 473–687)] before and after the introduction of a gluten-free diet (GFD). To this end, sera from 64 celiac disease (CD) subjects on a gluten-containing diet (44 f, 20 m) and after 0.6 ± 0.3 years and 2.1 ± 1.3 years of GFD were studied using a quantitative radioimmunoprecipitation assay. All 64 CD patients at diagnosis were full-length anti-tTG (a.a. 1–687)Ab positive. These Abs significantly decreased in frequency and titer after 6 months and 2 years of GFD. However, at low titers, 64.1% (41/64) of CD patients were still fl-tTG (a.a. 1–687)Ab positive after 2 years of GFD. At disease diagnosis, 70.3% (45/64) of the CD patients had Abs directed against fragments (227–687) and/or (473–687) of the tTG protein. This percentage, after 2 years of GFD, significantly decreased to 18.7%, whereas almost 50% of GFD patients had no tTG (227–687) and tTG (473–687) fragment reactivity, but only persistent, low-titer full-length tTG (1–687)Abs. We suggest that the selective loss of immunoreactivity against tTG (227–687) and tTG (473–687) fragments in CD patients with a GFD, could be due to quantitative decrease of autoreactivity driven by tTG-gliadin interaction underlying celiac disease pathogenesis.

Keywords: Celiac disease; Human tissue transglutaminase; Epitopes; Autoimmunity

Article Outline

Introduction
Materials and methods
Subjects
tTG constructs utilized in the study
Autoantibody radioimmunoassays
EMA detection
Statistical analysis
Results
Full-length tissue transglutaminase antibodies [fl-tTG (a.a. 1–687)Abs]
At diagnosis
After 6 months of GFD
After 2 years of GFD
tTG (a.a. 227–687)Abs
At diagnosis
After 6 months of GFD
After 2 years of GFD
tTG (a.a. 473–687)Abs
At diagnosis
After 6 months of GFD
After 2 years of GFD
EMA
Discussion
Acknowledgements
References



Clinical Immunology
Volume 121, Issue 1, October 2006, Pages 40-46
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.